このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

TeleStroke-Guided Thrombolysis for Acute Ischemic Stroke in Oman

2026年7月19日 更新者:Oman Ministry of Health

Thrombolysis for Acute Ischemic Stroke Facilitated by TeleStroke: Oman TeleStroke Initiative

The goal of this study is to establish and examine the efficacy of using a Telestroke network in Oman to facilitate using emergent thrombolysis for patients with acute ischemic stroke encountered in selected peripheral hospitals. It is proposed to establish a TeleStroke network involving two central hospitals in Muscat linked to three to five peripheral hospitals in Oman which currently have access to CT scans and basic infrastructure for management of AIS patients- but do not have a Neurology service. Selected staff from Internal Medicine/Emergency Medicine departments, Nursing, Technical service and support staffs will be trained in the process of assessment and management of AIS patients including the use of IV alteplase or tenecteplase. They will also be trained in timely access of a Neurologist on call at the central hospital(s) using a TeleStroke network. The Neurologist would conduct a Telestroke based clinical assessment of the AIS patient, review imaging and laboratory results in a timely manner and advice the medical team at the peripheral hospital regarding administration of IV alteplase/tenecteplase. The main purpose of such consultation would be to recognize eligible patients for administration of IV thrombolysis safely at the earliest opportunity within 4.5 hours, leading to increased rates of such thrombolysis with expected improved outcomes. Outcomes would be compared among 100 patients with AIS managed across these 5 hospitals prior to initiation of the practice of thrombolysis and at least 100 patients treated each with IV alteplase using TeleStroke Consultation with Neurologist. Demonstration of efficacy of TeleStroke based stroke thrombolysis would lead to effective implementation of this practice in Oman.

調査の概要

状態

まだ募集していません

詳細な説明

Stroke is the second leading cause of death globally and the primary cause of long-term disability. Timely management of acute ischemic stroke (AIS) requires emergent administration of intravenous thrombolytics (alteplase or tenecteplase) within 4.5 hours of symptom onset, often followed by triage for possible thrombectomy. However, many peripheral hospitals, particularly in regions like Oman, lack the specialized neurological expertise necessary for this time-sensitive management.

Telemedicine, specifically 'TeleStroke,' has emerged as a crucial solution in numerous countries and communities to bridge this gap, enabling remote neurological support for acute stroke thrombolysis. The Oman TeleStroke Initiative aims to establish and evaluate the efficacy of such a network.

Study Objectives:

This study aims to:

Establish a TeleStroke 'hub' center within one or two major hospitals in Muscat with existing neurologic services.

Develop 'spoke' TeleStroke centers in five peripheral hospitals (Rustaq, Ibra, Buraimi, Ibri, and Sur) by identifying and engaging multidisciplinary participating teams (Internal Medicine, Emergency Medicine, Imaging, Laboratory, Nursing, Technical support).

Train senior physician-led teams at spoke hospitals in TeleStroke-based acute stroke management protocols, specifically focusing on intravenous thrombolysis.

Educate broader medical and paramedical teams in overall acute stroke management and decision-making processes.

Sequentially initiate acute stroke thrombolysis services at peripheral centers following a stepped-wedge trial model.

Conduct 3-5 mock TeleStroke-based stroke thrombolysis cycles at each peripheral center to ensure readiness and troubleshoot protocols.

Support and monitor 20 stroke care encounters for thrombolysis at each spoke center.

Document demographic data, stroke type and severity (NIH Stroke Scale, GCS), main neurologic deficits, risk factors, discharge outcome (neurologic deficits; NISS; modified Rankin Score), and 3-month outcome for two patient groups at each center: 30 patients receiving conventional management before TeleStroke initiation and 20 patients after TeleStroke-facilitated thrombolysis.

Conduct a comprehensive cost-benefit analysis.

Compare outcomes and cost-benefit between cohorts before and after TeleStroke initiation.

Facilitate handover of the project to a standing committee managed by participating hospitals upon project completion.

Study Design and Setting:

This is an implementation study utilizing a stepped-wedge randomized trial model. The project will establish a TeleStroke network comprising one or two expert 'hub' hospitals in Muscat linked to five 'spoke' hospitals in the periphery (Rustaq, Ibra, Buraimi, Ibri, and Sur). The sequential initiation of thrombolysis services at spoke centers under TeleStroke guidance will allow for observation of conventional management (control phase) followed by the intervention phase at each site.

Intervention and Training:

The intervention involves the implementation of a TeleStroke network and comprehensive training. At peripheral hospitals, 2-3 dedicated senior physicians from Internal Medicine and Emergency Medicine will be trained in acute stroke management, focusing on thrombolytic care. This training will include didactic lectures, case discussions, hands-on sessions (e.g., NIH Stroke Scale administration), CT evaluation in acute stroke, thrombolysis decision-making, post-thrombolysis care, and communication skills. Related medical and paramedical teams (Nursing, Physical Medicine) will also receive training in overall acute stroke and post-stroke patient management. Essential IT infrastructure (computers with audio-video, image/lab upload capabilities) will be provided, and a dedicated computer application for systematic communication and documentation will be adapted. Mock encounters will be practiced at each center to refine protocols and achieve short door-to-needle times.

Key Management Steps:

Eligible patients will undergo a rapid assessment including focused history ("last known to be normal" time), neurological exam (NIHSS, GCS), vital signs, and urgent investigations (blood glucose, CBC, U&E, ECG, CT brain plain, with CTA if available). If eligible for IV alteplase, consent will be obtained, and a TeleStroke consultation with a neurologist will be initiated. The remote neurologist will confirm eligibility, review imaging and labs, confirm consent, recommend the alteplase dose (0.9 mg/kg total, 10% bolus over 2 min, remainder over 1 hour), and guide post-dosing care. Patients will be monitored for BP, sensorium, deficits, and hemorrhage, with repeat CT at 24 hours or earlier if worsening. Patients with poor neurological status or complications may be transferred to a central hospital for expert care. Follow-up will extend to 3 months.

Endpoints of Interest:

Primary Outcomes:

Rate of utilization of IV alteplase thrombolysis for AIS at peripheral hospitals.

3-month clinical outcomes (Good=mRS 0-2; Poor=mRS 3-6) comparing control and rtPA groups.

Rates of intracranial or systemic hemorrhage.

Secondary Outcomes:

Discharge clinical outcomes (Good=mRS 0-2; Poor=mRS 3-6) comparing control and rtPA groups.

Time from patient arrival to initiation of TeleStroke Consult.

Door-to-Needle time for rtPA administration.

Rates of TeleStroke Consultations for acute stroke from peripheral hospitals.

Frequency of patient transfers to central hospitals.

Frequency of ICU admissions required.

Estimated cost of care: Comparison among Controls and rtPA Groups.

Statistical Analysis:

A stepped-wedge randomized model will guide implementation. Data from 30 patients managed conventionally will be documented at each center prior to thrombolysis initiation. After at least 20 thrombolysis encounters per peripheral hospital, overall outcomes will be analyzed. Continuous variables will be summarized using means/SDs or medians/quartiles, and categorical variables using frequencies/percentages. Analyses will be 2-tailed (p<0.05) using SPSS-21. Univariate methods will compare endpoints, and logistic regression will explore factors influencing outcomes. Cost-benefit analysis will compare TeleStroke-based management to conventional methods.

Significance to Oman and Benefits:

This initiative addresses a critical gap in acute ischemic stroke care by extending access to thrombolysis, currently largely inaccessible in many Omani peripheral communities. Successful implementation will align Omani stroke care with current international standards, potentially reducing stroke-related mortality and long-term morbidity. The expected reduction in long-term disability care costs is anticipated to offset program implementation and management expenses. This project will also foster ongoing skilled manpower development in acute care, telemedicine, and TeleStroke technology within Oman. While replicating studies conducted elsewhere, this research is vital to address local limitations such as telecommunications access, technological constraints, and community/hospital acceptability specific to Oman.

研究の種類

介入

入学 (推定)

200

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Arunodaya R Gujjar, MD, FRCP
  • 電話番号:+968 95154022
  • メール:arunoday@squ.edu.om

研究連絡先のバックアップ

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Age >18 years. Acute neurologic deficits due to cerebral ischemia/infarction. Clearly defined onset with duration from stroke onset of <4.5 hours. Significant neurological deficit (usually NIHSS score of 4-25).

Exclusion Criteria:

  • CT brain shows showing evidence of intracranial hemorrhage
  • CT brain showing acute or subacute infarct of size about >1/3 Middle Cerebral Artery territory.
  • Arterial puncture at non compressible site in previous 7 days
  • History of previous intracranial hemorrhage.
  • Intracranial neoplasm, AV malformation, or aneurysm
  • Recent head injury OR intracranial or intraspinal surgery in last 3 mo.
  • Persistent Elevated BP >185/110 mm Hg despite treatment.
  • Active ongoing internal bleeding.
  • Platelet count <100 000/mm3.
  • Current use of NOACs OR warfarin with INR >1.7 OR Inj.Enoxaparin/Heparin in therapeutic dose
  • Blood glucose concentration <2.7mmol/L (<50mg/dl).

Relative contraindications: (may consider IV alteplase on individual evaluation).

  • Seizure at onset with post ictal residual neurological deficit.
  • Signs of mild stroke in isolation or rapidly improving symptoms.
  • Pregnancy.
  • Recent GI or UT hemorrhage within the last 21 days.
  • Recent MI within previous 3 months (to exclude anterolateral infarct / STEMI)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Thrombolysis arm
This arm includes patients with Acute ischemic stroke treated with thrombolysis using TeleStroke consultation
Thrombolysis using TeleStroke consultation with Neurologist
他の名前:
  • rt-PA, TNK
介入なし:Control Arm
This arm includes age, gender matched patients with Acute Ischemic stroke who are not treated by thrombolysis.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
90 day outcome
時間枠:90 days
Clinical outcome on modified Rankin Score at 90 days. This scale rates outcome from 0 to 6, with 0=no symptoms, 5=bed bound requiring assistance, 6=dead.
90 days
Discharge Outcome
時間枠:At discharge (assessed up to 5 days)
Clinical outcome on modified Rankin Score at discharge from hospital (assessed up to 5 days). This scale rates outcome from 0 to 6, with 0=no symptoms, 5=bed bound requiring assistance, 6=dead.
At discharge (assessed up to 5 days)
Rate of Thrombolysis
時間枠:At admission and initial management- 2 hours
Rate of utilization of IV alteplase / tenecteplase thrombolysis for acute ischemic stroke at peripheral hospitals
At admission and initial management- 2 hours

二次結果の測定

結果測定
メジャーの説明
時間枠
Intracranial Hemorrhage Rate
時間枠:24 hours
Rate of symptomatic intracranial hemorrhage at 24 hours of IV thrombolysis
24 hours
Door to Needle time
時間枠:1 hour
Time from Triage arrival of patient to time IV thrombolysis is initiated
1 hour

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Arunodaya R Gujjar, MD, DM, FRCP、College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman
  • スタディディレクター:Sanjay Jaju, MD、College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月1日

一次修了 (推定)

2026年12月30日

研究の完了 (推定)

2027年3月30日

試験登録日

最初に提出

2025年7月16日

QC基準を満たした最初の提出物

2026年7月19日

最初の投稿 (実際)

2026年7月22日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月22日

QC基準を満たした最後の更新が送信されました

2026年7月19日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

After completion of study, anonymized IPD data can be shared on request by eligible researchers.

IPD 共有時間枠

Dec 2026 to Dec 2027

IPD 共有アクセス基準

After completion of study, anonymized IPD data can be shared on request by eligible researchers.

IPD 共有サポート情報タイプ

  • SAP
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する